<DOC>
	<DOC>NCT01254630</DOC>
	<brief_summary>This is a randomized, double-blind, placebo-controlled study to assess the safety and tolerability of V212 when administered to adults with solid tumor malignancy (STM) or hematologic malignancy (HM) and to determine whether V212 reduces the incidence of herpes zoster (HZ) in adults with STM or HM, as compared to placebo.</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011)</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criteria; Participant has been diagnosed with an STM or HM and is not likely to undergo hematopoietic cell transplant (HCT) and: Participant is ≥18 years of age and receiving a cytotoxic or immunosuppressive chemotherapy regimen Participant is ≥ 50 years of age with a hematologic malignancy that is not in remission, whether on therapy or not Participant has a life expectancy ≥ 12 months. Participant has prior history of varicella or antibodies to VZV due to exposure to the disease in a country where the disease is common. Exclusion criteria: Participant has a history of allergic reaction to any vaccine component (including gelatin) or an anaphylactic/anaphylactoid reaction to neomycin. Participant has a prior history of HZ within 1 year of enrollment. Participant has received or is expected to receive any varicella or nonstudy zoster vaccine. Participant is currently receiving or expected to receive longterm antiviral prophylaxis (&gt;4 weeks duration) with activity against herpes simplex virus (HSV), VZV or cytomegalovirus (CMV) Participant is pregnant or breastfeeding or expecting to conceive within the period of 2 weeks prior to enrollment throughout 6 months after last vaccination dose. Participant has had any live virus vaccine administered or scheduled in the period from 4 weeks prior to Dose 1 through 28 days post vaccination dose 4 Participant has had inactivated vaccine administered or scheduled within the period from 7 days prior to, through 7 days following, any dose of study vaccine.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Herpes zoster</keyword>
	<keyword>vaccine</keyword>
	<keyword>solid tumor malignancy</keyword>
	<keyword>hematologic malignancy</keyword>
	<keyword>immunocompromised</keyword>
	<keyword>herpes-zoster-related complications</keyword>
</DOC>